methadone and Deglutition Disorders

methadone has been researched along with Deglutition Disorders in 1 studies

Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.

Deglutition Disorders: Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.

Research

Studies (1)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in Pill Swallowing Difficulty Score

"Pill swallowing difficulty will be measured via a 0-10 scale with 0 being no trouble at all and 10 being the greatest difficulty possible. Responses will be summarized as change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study. Baseline covers current opioid medication, and week 6 covers Xtampza ER.

Effect of Xtampza ER Conversion on Pain Intensity in the Last 24 Hours

"Percent change in pain intensity (in the last 24 hours) from baseline to the end of the study averaged over the last 7 days before clinic visit 4 (week 6). Pain Intensity is measured on a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable. As decreases in pain intensity are a sign of improvement, percent change in pain intensity is calculated as -(end of study - baseline)/baseline score." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study

Effect of Xtampza ER Conversion on Pain Intensity in the Last 7 Days

"Percent change in pain intensity (in the past 7 days) from baseline to the end of the study at clinic visit 4 (week 6). Pain Intensity is measured on a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable. As decreases in pain intensity are a sign of improvement, percent change in pain intensity is calculated as -(end of study - baseline)/baseline score." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study

Opioid Medication Satisfaction

"Opioid medication satisfaction will be measured via a 0-10 scale with 0 being not satisfied at all and 10 being completely satisfied. Responses will be summarized as change from baseline score to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study. Recorded baseline for current opioid medication and in week 6 for Xtampza ER.

Patient Global Impression of Change (PGIC)

The subject's impression of the impact of the treatment on their pain and function will be measured with a 7-item scale (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved). Responses will be summarized as individual mean scores at clinic visit 4 (week 6). (NCT03588806)
Timeframe: Recorded in week 6.

Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference

"The Pain Interference questions (#25-28) from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 1 being Not at all and 5 being Very much. Responses will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. Pain Interference T-Scores will be summarized as the change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study

PROMIS Physical Function

"The Physical Function questions (#1-4) from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 5 being Without any difficulty and 1 being Unable to do. Responses will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. Physical Function T-Scores will be summarized as change from baseline score to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study

PROMIS Depression, Anxiety, Satisfaction With Social Roles, and Sleep Disturbance

"The Depression (#9-12), Anxiety (#5-8), Satisfaction with Social Roles (#21-24), and Sleep Disturbance (#17-20) questions from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 1 being Never and 5 being Always. Responses for each section will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. These T-Scores will be summarized as change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study

Other Studies

1 other study available for methadone and Deglutition Disorders